BTAI - Company ID 0001720893
BioXcel Therapeutics, Inc. trades as BTAI. In its fiscal 2025 annual report the company posted revenue of $642.00K, down 71.7% from the prior year and net income of -$69.90M. This page tracks BioXcel Therapeutics, Inc. through 656 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Net profit margin expanded from -44201.9% to -10887.4% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider sale notice | 144 | 2026-05-20 |
| Insider sale notice | 144 | 2026-05-20 |
| Insider sale notice | 144 | 2026-05-20 |
| Insider sale notice | 144 | 2026-05-20 |
The largest companies sharing BioXcel Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
BioXcel Therapeutics, Inc. reported revenue of $642.00K for fiscal year 2025, a decrease of 71.7% year over year.
In its latest fiscal year BioXcel Therapeutics, Inc. reported a net loss of $69.90M.